Here are the 10-K annual reports from Zoetis Inc. (ZTS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ZTS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZTS filings page.
Zoetis Inc. is a global animal health company focused on medicines, vaccines, diagnostics and biodevices for companion animals and livestock. It operates in two segments: U.S. revenue was $5,097 million and International revenue was $4,254 million in 2025.
Companion animal products generated about 70% of 2025 revenue, livestock about 29%, with contract manufacturing and human health diagnostics around 1%. Flagship lines Simparica/Simparica Trio and Apoquel/Apoquel Chewable contributed roughly 16% and 12% of revenue; the top ten product lines made up about 57%.
Zoetis invested $698 million in R&D in 2025 across more than 300 programs and employed about 14,500 people worldwide. The company maintains a 21-site manufacturing network, extensive use of contract manufacturers, and operates under complex global regulatory, environmental, data privacy and AI-related frameworks.